Results for tag: "Interleukin 6 Inhibitors"

Interleukin 6 (IL-6) inhibitors are a class of therapeutic agents used in the treatment of various immune-mediated disorders. IL-6 is a cytokine that plays a crucial role in immune response and the inflammation process. Overproduction of IL-6 is associated with several chronic inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and Castleman's disease. The development of IL-6 inhibitors has been driven by the understanding that targeted immunomodulation can ameliorate symptoms and potentially alter the course of these diseases. The market for IL-6 inhibitors includes several biologic drugs that bind to either the IL-6 cytokine itself or its receptor, thereby preventing the cytokine from exerting its pro-inflammatory effects. Pharmaceutical companies with stakes in the IL-6 inhibitors market have engaged in research and development to expand the therapeutic applications of these drugs beyond their initial indications. The landscape is marked by ongoing clinical trials aimed at optimizing the efficacy and safety profiles of these treatments across a spectrum of immune disorders. Additionally, the drugs' patents, market exclusivity, and the introduction of biosimilars influence the dynamics of the market. Some companies involved in the IL-6 inhibitors market include Roche, which markets tocilizumab, a widely used IL-6 receptor antagonist; Sanofi and Regeneron Pharmaceuticals, which together developed sarilumab; and Eli Lilly, which offers an IL-6 antagonist called Show Less Read more